Abstract
Epileptic activity and neuronal excitability have been reported in the setting of Alzheimer’s disease (AD), and may be linked to disease progression and severity. A shift in the excitation/inhibition balance to favor a more excitatory-dominant outcome appears to underlie the overall hyperactivity, with key mechanisms known to regulate excitatory and inhibitory neurotransmission in the brain being primarily affected. Synaptic dysfunction is a critical event in AD pathogenesis. Recent research suggests that the zinc finger protein, ZCCHC17 (Zinc Finger CCHC-Type Containing 17), serves as a potential master regulator of synaptic dysfunction in AD, with expression significantly reduced in the AD brain prior to gliosis and neuronal loss. Reduced levels of ZCCHC17 have been shown to lead to abnormal RNA processing and neuronal hyperexcitability. This review examines the specific role of ZCCHC17 in the AD brain, and discusses how ZCCHC17 may regulate mechanisms that underlie neuronal hyperexcitability. New insight into synaptic regulators of disease may contribute to improvements in early-stage diagnostics and interventions, and may better guide therapeutic approaches aimed at rescuing synaptic dysfunction in the prodromal stages of AD.
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia (Alzheimer’s and Dementia, 2024). The accumulation of extracellular amyloid plaques composed of amyloid beta-protein (Aβ) and the formation of intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated tau are considered key pathological hallmarks of AD (Glenner and Wong, 1984; Grundke-Iqbal et al., 1986), and have therefore been a target for research and guided therapeutic approaches and diagnostic criteria. However, over the past few decades, AD treatments targeting these protein aggregates have yielded modest outcomes at best, resulting in high failure rates and limited effects among drug candidates (Klyucherev et al., 2022). There is strong evidence confirming that plaque formation and NFTs are associated with neurodegeneration (Chinnathambi et al., 2025). However, the role of plaques and NFTs as early molecular mechanisms remains in question, suggesting that additional factors surrounding AD pathogenesis and pathophysiology may also play a contributing role.
Significant efforts have been directed at uncovering interactions between protein aggregates and physiological and immunological irregularities, which include neuroinflammation, mitochondrial dysfunction, oxidative stress, and epileptiform activity (Cortese et al., 2024; Csernus et al., 2022; Gourmaud et al., 2022; Hering et al., 2025; Klyucherev et al., 2022; Tönnies and Trushina, 2017; Vossel et al., 2017). Studying these physiological and immunological processes may be useful for understanding early prodromal events prior to the onset of symptoms, and may also inform our understanding of disease progression and severity.
Neuronal hyperactivity is detected in the early stages of AD (Barbour et al., 2024; Cretin et al., 2016; Vossel et al., 2013, 2016), and may accelerate disease progression and cognitive decline (Baker et al., 2019; Horvath et al., 2021; Lott et al., 2012; Volicer et al., 1995; Vossel et al., 2017). Similar neurophysiological changes have been found in AD animal models (Barbour et al., 2024; Busche et al., 2008; Ciccone et al., 2019; Maier et al., 2014; Minkeviciene et al., 2009; Nygaard et al., 2015; Palop et al., 2007; Palop and Mucke, 2009, 2010; Sanchez et al., 2012; Zou et al., 2024). Aβ and hyperphosphorylated tau have been linked to neural hyperactivity in AD (Lam et al., 2022; Palop and Mucke, 2009; Vicente et al., 2024), and also associated with seizure disorders (Hwang et al., 2022; Romoli et al., 2021; Thom et al., 2011; Vicente et al., 2024). Mechanistically, AD-associated hyperactivity is thought to occur following disruptions to pre-, post-, and peri-synaptic mechanisms that underlie excitatory and inhibitory neurotransmission, shifting the balance of excitatory/inhibitory (E/I) activity in the brain (Barbour et al., 2024; Lauterborn et al., 2021). Numerous studies have confirmed that aberrant glutamatergic and GABAergic signaling disrupts the normal balance of E/I activity (Gong et al., 2009; Lauterborn et al., 2021; Limon et al., 2012; Palop et al., 2007; Vossel et al., 2017; Wakabayashi et al., 1999). Thus, identifying mechanisms, or key players contributing to the shift in E/I activity may be critical for understanding early molecular events responsible for AD pathogenesis. In addition, it is possible that comorbid conditions, including epileptic activity, may not only be correlated with AD but may also contribute significantly to AD pathogenesis.
This review discusses recent findings that characterized a novel synaptic mechanism by which synaptic dysfunction and hyperexcitability occurs in AD. Specifically, we highlight the initial discovery that ZCCHC17, a master regulator of synaptic gene expression (Bartosch et al., 2024; Tomljanovic et al., 2018), which is significantly reduced in AD brain prior to gliosis and neuronal loss (Tomljanovic et al., 2018) and causes neuronal hyperexcitability in a neuronal model (Cortese et al., 2024). This provides a potential novel target for diagnostic and therapeutic strategies to preserve cognitive function surrounding AD pathology.
Synaptic dysfunction in AD
It is widely recognized that synaptic failure is an early event in AD (Selkoe, 2002), and is thought to underlie cognitive impairment during the earliest clinical phases of the disease (Chen et al., 2019; Li and Selkoe, 2020). Synapse loss precedes overall neuronal loss and correlates with premortem cognitive status (de Wilde et al., 2016; DeKosky and Scheff, 1990; Hamos et al., 1989; Robinson et al., 2014; Terry et al., 1991). Aβ and tau may have normal roles at the synapse that is relevant for how these protein aggregates contribute to neurodegeneration, which directly links synaptic dysfunction to the two disease-defining proteins of Alzheimer’s disease (Spires-Jones and Hyman, 2014). Additional evidence linking Alzheimer’s disease to neuronal hyperactivity comes from studying genetically influenced disease. For example, homozygous carriers of the ε4 allele of Apolipoprotein E (APOE4), a well-established genetic risk factor AD, show an increased risk for late-onset epilepsy with dementia (Johnson et al., 2018; Liang et al., 2019). Furthermore, patients with familial forms of AD have a seizure rate approaching 30% in some studies (Shea et al., 2016). Similarly, individuals with Trisomy 21 (Down syndrome) have an increased risk of seizures (Rahman and Fatema, 2019). Despite all this evidence, the specific mechanisms by which genetic risk promotes hyperexcitability, and the chain of causality, are not well understood.
Epileptiform activity in AD
Similarly to genetic risk studies, it has also been noted that AD patients in the general population have an elevated risk for developing seizures and epilepsy (Horváth et al., 2016, 2018; Vossel et al., 2013). More than 40% of AD patients present with a subclinical epileptiform activity (SEA), as characterized by isolated epileptiform discharges without overt epileptic seizures (Horváth et al., 2018; Horvath et al., 2021; Vossel et al., 2013, 2016). Reports of overt seizure in AD range widely in the literature, although most studies show increased risk, ranging up to 20% of patients over the disease course in some studies (Yang et al., 2022), with common occurrences in younger AD patients (Sherzai et al., 2014; Vossel et al., 2013). Periods of network hyperexcitability and SEA within the brain are known to occur during the early, presymptomatic stages of AD (Cretin et al., 2016; Quiroz et al., 2010; Ranasinghe et al., 2022; Sarkis et al., 2016; Sepulveda-Falla et al., 2012; Vossel et al., 2013, 2016). It’s worth noting, however, that similar activity has been shown to occur during later stages of AD (Hauser et al., 1986; Sherzai et al., 2014; Vossel et al., 2017). Given the difficulty in observing non-motor seizures in patients, most SEA and hyperactive events go undetected. Several studies in AD patients and animal models have confirmed the pathogenicity surrounding these hyperactive events (Baker et al., 2019; Barbour et al., 2024; Hector and Brouillette, 2020; Horváth et al., 2016, 2018; Vossel et al., 2013, 2017). Given that the balance between excitatory and inhibitory neurotransmission, as determined by postsynaptic currents through excitatory glutamate and inhibitory GABA signaling, is necessary for normal network function (Barral and D Reyes, 2016; Zhou and Yu, 2018), it has been proposed that shifting of the E/I balance to favor excitatory glutamatergic neurotransmission may contribute to the overall network hyperactivity in AD (Lauterborn et al., 2021; Vicente et al., 2024). Furthermore, Lauterborn et al. (2021) confirmed that the E/I imbalance favoring hyperexcitability in AD can occur despite synapse loss. Excess glutamate activity and reduced GABAergic synaptic activity occur in AD and epilepsy, potentially leading to excitotoxicity and driving the neurodegeneration seen later in AD pathology (Barker-Haliski and White, 2015; Calvo-Rodriguez and Bacskai, 2021; Vicente et al., 2024; Yu et al., 2025). Presynaptic (Akyuz et al., 2021; Anschuetz et al., 2024; Fukata and Fukata, 2017; Jiang et al., 2025; Sze et al., 1997), perisynaptic (Akyuz et al., 2021; Anschuetz et al., 2024; Fukata and Fukata, 2017; Jiang et al., 2025; Sze et al., 1997), and postsynaptic (Akyuz et al., 2021; Brines et al., 1997; Escamilla et al., 2024; Fukata and Fukata, 2017; Govindpani et al., 2020; Kwakowsky et al., 2018; Mathern et al., 1997, 1998; Ning et al., 2024; Osse et al., 2023) changes are commonly observed.
ZCCHC17 and AD
Gueydan et al. (2002) first discovered ZCCHC17 (Zinc Finger CCHC-Type Containing 17) while screening a cDNA library for RNA binding proteins. Additionally, ZCCHC17 (also known as pNO40) was independently identified by Chang et al. (2003) via a yeast 2-hybrid screen for pinin-interacting proteins. ZCCHC17 has an S1 RNA-binding domain and a zinc-finger (CCHC) domain, with two nuclear localization signals. Although highly expressed in brain, ZCCHC17 transcripts are found throughout the body, including in heart, skeletal muscle, and thymus (Chang et al., 2003). Current evidence suggests that ZCCHC17 has roles in both mRNA (Lin et al., 2017) and rRNA (Lin et al., 2019) processing, and that it may coordinate a variety of homeostatic cellular functions (Lin et al., 2017).
More than a decade after the discovery of ZCCHC17, ZCCHC17 was shown to be implicated in AD pathology (Li et al., 2015; Tomljanovic et al., 2018). Using novel data mining techniques to identify molecular drivers of synaptic dysfunction in AD, Tomoljanovic et al. (2018) demonstrated that ZCCHC17 is normally expressed in neurons and is reduced in expression in human AD tissue from temporal cortex during the early course of pathology prior to significant gliosis and neuronal loss. Subsequently, they modeled ZCCHC17 knockdown in primary cortical neurons, and confirmed that loss of ZCCHC17 leads to reduced expression of several dozen synaptic targets; including presynaptic genes SV2B (Synaptic Vesicle Glycoprotein 2B), SYT1 (synaptotagmin-1), and SYN2 (synapsin 2), suggesting a role as a transcriptional regulator whose dysfunction in AD contributes to synaptic dysregulation (Tomljanovic et al., 2018) (see Figure 1 for summary of discussion in this section). Building on this work, Bartosch et al. (2024) showed that ZCCHC17 knock-down in human iPSC-derived neurons partially reproduces synaptic gene-splicing abnormalities seen in AD brain tissue, and further showed that ZCCHC17 expression correlates with cognitive resilience in the setting of AD pathology. Interestingly, the work of Bartosch et al. (2024) also uncovered an APOE4-dependent correlation of ZCCHC17 expression with NFT burden, and further showed that ZCCHC17 knock-down and tau overexpression lead to shared spicing abnormalities in neurons, suggesting a relationship between tau dysfunction and ZCCHC17 impairment. In an attempt to study the functional consequences of impaired ZCCHC17 function, Cortese et al. (2024) demonstrated that loss of ZCCHC17 partially phenocopies AD-related loss of synaptic proteins and hyperexcitability. Using an in vitro model of siRNA knockdown of ZCCHC17 in primary cortical neurons, Cortese et al. (2024) demonstrated that there was a shift in excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission, favoring an excitatory-dominant system that caused neuronal hyperactivity on a single-cell level, and showed that these changes are accompanied by reduced levels of postsynaptic glutamate (GluA1) and GABAA receptors and postsynaptic scaffold proteins Shank3 and Gephyrin. Note that while Cortese et al. (2024) did not show how reduced excitatory and inhibitory input leads to overall hyperexcitability in their model, others have found similar results in AD tissue and shown that there is an overall net increase in excitation after loss of both excitatory and inhibitory inputs (Lauterborn et al., 2021). It should also be noted that the exact role of ZCCHC17 in the nucleus is still being investigated, and this raises questions as to how ZCCHC17 loss leads to reduced expression and aberrant splicing of synaptic genes. Outstanding questions aside, the above findings have furthered our understanding of the functional role of ZCCHC17 knock-down in neurons, and may provide a new perspective for understanding and targeting early events in AD.
FIGURE 1
The physiological and biological consequences of reduced ZCCHC17 in the AD brain. Created in BioRender. Cortese, G. (2026) https://BioRender.com/d61fup3.
Conclusion
In conclusion, a multifaceted network of presynaptic, perisynaptic, and postsynaptic dysregulation leads to neuronal hyperexcitability. Recent studies have documented comparable physiological phenotypes in AD brain and have shed further light on the role of synaptic dysfunction in AD and its value as a potential therapeutic target. ZCCHC17 is reduced in the AD brain before gliosis and neuronal loss, and studies have supported a role for ZCCHC17 in AD-related synaptic dysfunction. Specifically, reductions in ZCCHC17 have been shown to result in: (1) decreased expression of several synaptic genes (Tomljanovic et al., 2018), (2) abnormal RNA processing affecting synaptic genes (Bartosch et al., 2024), and (3) phenocopies of AD-related loss of synaptic proteins and hyperexcitability (Cortese et al., 2024). Converging data suggests that mechanisms underlying excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission, including but not limited to presynaptic transporters and vesicle fusion proteins and postsynaptic inotropic and metabotropic receptors, may contribute to AD pathogenesis. (see Figure 1 proposing potential pre- and postsynaptic mechanisms that may give rise to hyperexcitability). Future studies aimed at determining how impaired ZCCHC17 function impacts synaptic function in AD are merited. Further exploration of ZCCHC17 function in models of genetic predisposition to AD, like Down syndrome, as well as models of multiple forms of epilepsy, may also illuminate the role of ZCCHC17 as an early target. To date, these studies have not been done but hold promise for providing a novel portal for exploration of AD.
Statements
Author contributions
AT: Conceptualization, Writing – review & editing. GC: Supervision, Writing – review & editing, Conceptualization, Writing – original draft. BK: Writing – review & editing, Visualization.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Institute of General Medical Sciences under Award Number 5P20GM152335 to the McLaughlin Research Institute.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Author disclaimer
The content is solely the responsibility of authors and does not necessarily represent the official views of the National Institutes of Health.
References
1
Akyuz E. Polat A. K. Eroglu E. Kullu I. Angelopoulou E. Paudel Y. N. (2021). Revisiting the role of neurotransmitters in epilepsy: An updated review.Life Sci.265:118826. 10.1016/j.lfs.2020.118826
2
Alzheimer’s and Dementia (2024). 2024 Alzheimer’s disease facts and figures.Alzheimers Dement.203708–3821. 10.1002/alz.13809
3
Anschuetz A. Schwab K. Harrington C. R. Wischik C. M. Riedel G. (2024). A meta-analysis on presynaptic changes in Alzheimer’s disease.J. Alzheimers Dis.97145–162. 10.3233/JAD-231034
4
Baker J. Libretto T. Henley W. Zeman A. (2019). A longitudinal study of epileptic seizures in Alzheimer’s disease.Front. Neurol.10:1266. 10.3389/fneur.2019.01266
5
Barbour A. J. Gourmaud S. Lancaster E. Li X. Stewart D. A. Hoag K. F. et al (2024). Seizures exacerbate excitatory: Inhibitory imbalance in Alzheimer’s disease and 5XFAD mice.Brain1472169–2184. 10.1093/brain/awae126
6
Barker-Haliski M. White H. S. (2015). Glutamatergic mechanisms associated with seizures and epilepsy.Cold Spring Harb. Perspect. Med.5:a022863. 10.1101/cshperspect.a022863
7
Barral J. D Reyes A. (2016). Synaptic scaling rule preserves excitatory-inhibitory balance and salient neuronal network dynamics.Nat. Neurosci.191690–1696. 10.1038/nn.4415
8
Bartosch A. M. W. Youth E. H. H. Hansen S. Wu Y. Buchanan H. M. Kaufman M. E. et al (2024). ZCCHC17 modulates neuronal RNA splicing and supports cognitive resilience in Alzheimer’s disease.J. Neurosci.44:e2324222023. 10.1523/JNEUROSCI.2324-22.2023
9
Brines M. L. Sundaresan S. Spencer D. D. de Lanerolle N. C. (1997). Quantitative autoradiographic analysis of ionotropic glutamate receptor subtypes in human temporal lobe epilepsy: Up-regulation in reorganized epileptogenic hippocampus.Eur. J. Neurosci.92035–2044. 10.1111/j.1460-9568.1997.tb01371.x
10
Busche M. A. Eichhoff G. Adelsberger H. Abramowski D. Wiederhold K.-H. Haass C. et al (2008). Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease.Science3211686–1689. 10.1126/science.1162844
11
Calvo-Rodriguez M. Bacskai B. J. (2021). Mitochondria and calcium in Alzheimer’s disease: From cell signaling to neuronal cell death.Trends Neurosci.44136–151. 10.1016/j.tins.2020.10.004
12
Chang W.-L. Lee D.-C. Leu S. Huang Y.-M. Lu M.-C. Ouyang P. (2003). Molecular characterization of a novel nucleolar protein, pNO40.Biochem. Biophys. Res. Commun.307569–577. 10.1016/s0006-291x(03)01208-7
13
Chen Y. Fu A. K. Y. Ip N. Y. (2019). Synaptic dysfunction in Alzheimer’s disease: Mechanisms and therapeutic strategies.Pharmacol. Ther.195186–198. 10.1016/j.pharmthera.2018.11.006
14
Chinnathambi S. Kumarappan M. Chandrashekar M. Malik S. (2025). The aggregation propensity of Tau and amyloid-β in Alzheimer’s disease.Adv. Protein Chem. Struct. Biol.146179–199. 10.1016/bs.apcsb.2024.10.004
15
Ciccone R. Franco C. Piccialli I. Boscia F. Casamassa A. de Rosa V. et al (2019). Amyloid β-induced upregulation of Nav1.6 underlies neuronal hyperactivity in Tg2576 Alzheimer’s disease mouse model.Sci. Rep.9:13592. 10.1038/s41598-019-50018-1
16
Cortese G. P. Bartosch A. M. W. Xiao H. Gribkova Y. Lam T. G. Argyrousi E. K. et al (2024). ZCCHC17 knockdown phenocopies Alzheimer’s disease-related loss of synaptic proteins and hyperexcitability.J. Neuropathol. Exp. Neurol.83626–635. 10.1093/jnen/nlae033
17
Cretin B. Sellal F. Philippi N. Bousiges O. Di Bitonto L. Martin-Hunyadi C. et al (2016). Epileptic prodromal Alzheimer’s disease, a retrospective study of 13 new cases: Expanding the spectrum of Alzheimer’s disease to an epileptic variant?J. Alzheimers Dis.521125–1133. 10.3233/JAD-150096
18
Csernus E. A. Werber T. Kamondi A. Horvath A. A. (2022). The significance of subclinical epileptiform activity in Alzheimer’s disease: A review.Front. Neurol.13:856500. 10.3389/fneur.2022.856500
19
de Wilde M. C. Overk C. R. Sijben J. W. Masliah E. (2016). Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability.Alzheimers Dement.12633–644. 10.1016/j.jalz.2015.12.005
20
DeKosky S. T. Scheff S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity.Ann. Neurol.27457–464. 10.1002/ana.410270502
21
Escamilla S. Sáez-Valero J. Cuchillo-Ibáñez I. (2024). NMDARs in Alzheimer’s disease: Between synaptic and extrasynaptic membranes.Int. J. Mol. Sci.25:10220. 10.3390/ijms251810220
22
Fukata Y. Fukata M. (2017). Epilepsy and synaptic proteins.Curr. Opin. Neurobiol.451–8. 10.1016/j.conb.2017.02.001
23
Glenner G. G. Wong C. W. (1984). Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein.Biochem. Biophys. Res. Commun.120885–890. 10.1016/s0006-291x(84)80190-4
24
Gong Y. Lippa C. F. Zhu J. Lin Q. Rosso A. L. (2009). Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer’s disease.Brain Res.1292191–198. 10.1016/j.brainres.2009.07.056
25
Gourmaud S. Stewart D. A. Irwin D. J. Roberts N. Barbour A. J. Eberwine G. et al (2022). The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer’s disease.Brain145324–339. 10.1093/brain/awab268
26
Govindpani K. Turner C. Waldvogel H. J. Faull R. L. M. Kwakowsky A. (2020). Impaired expression of GABA signaling components in the Alzheimer’s disease middle temporal gyrus.Int. J. Mol. Sci.21:8704. 10.3390/ijms21228704
27
Grundke-Iqbal I. Iqbal K. Tung Y. C. Quinlan M. Wisniewski H. M. Binder L. I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.Proc. Natl. Acad. Sci. U. S. A.834913–4917. 10.1073/pnas.83.13.4913
28
Gueydan C. Wauquier C. De Mees C. Huez G. Kruys V. (2002). Identification of ribosomal proteins specific to higher eukaryotic organisms.J. Biol. Chem.27745034–45040. 10.1074/jbc.M208551200
29
Hamos J. E. DeGennaro L. J. Drachman D. A. (1989). Synaptic loss in Alzheimer’s disease and other dementias.Neurology39355–361. 10.1212/wnl.39.3.355
30
Hauser W. A. Morris M. L. Heston L. L. Anderson V. E. (1986). Seizures and myoclonus in patients with Alzheimer’s disease.Neurology361226–1230. 10.1212/wnl.36.9.1226
31
Hector A. Brouillette J. (2020). Hyperactivity induced by soluble amyloid-β oligomers in the early stages of Alzheimer’s disease.Front. Mol. Neurosci.13:600084. 10.3389/fnmol.2020.600084
32
Hering H. Bussiere T. Liu C.-C. Glajch K. E. Weihofen A. Grogan J. et al (2025). A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies.Mol. Neurodegener.20:88. 10.1186/s13024-025-00872-7
33
Horváth A. Szűcs A. Barcs G. Noebels J. L. Kamondi A. (2016). Epileptic seizures in Alzheimer disease.Alzheimer Dis. Assoc. Disord.30186–192. 10.1097/WAD.0000000000000134
34
Horváth A. Szűcs A. Hidasi Z. Csukly G. Barcs G. Kamondi A. (2018). Prevalence, semiology, and risk factors of epilepsy in Alzheimer’s disease: An ambulatory EEG study.J. Alzheimers Dis.631045–1054. 10.3233/JAD-170925
35
Horvath A. A. Papp A. Zsuffa J. Szucs A. Luckl J. Radai F. et al (2021). Subclinical epileptiform activity accelerates the progression of Alzheimer’s disease: A long-term EEG study.Clin. Neurophysiol.1321982–1989. 10.1016/j.clinph.2021.03.050
36
Hwang K. Vaknalli R. N. Addo-Osafo K. Vicente M. Vossel K. (2022). Tauopathy and epilepsy comorbidities and underlying mechanisms.Front. Aging Neurosci.14:903973. 10.3389/fnagi.2022.903973
37
Jiang K. Yang L.-T. Xue M. (2025). Breaking the synaptic vesicle cycle: Mechanistic insights into presynaptic dysfunctions in epilepsy.Epilepsy Curr.25119–124. 10.1177/15357597251317898
38
Johnson E. L. Krauss G. L. Lee A. K. Schneider A. L. C. Dearborn J. L. Kucharska-Newton A. M. et al (2018). Association between midlife risk factors and late-onset epilepsy: Results from the atherosclerosis risk in communities study.JAMA Neurol.751375–1382. 10.1001/jamaneurol.2018.1935
39
Klyucherev T. O. Olszewski P. Shalimova A. A. Chubarev V. N. Tarasov V. V. Attwood M. M. et al (2022). Advances in the development of new biomarkers for Alzheimer’s disease.Transl. Neurodegener.11:25. 10.1186/s40035-022-00296-z
40
Kwakowsky A. Calvo-Flores Guzmán B. Pandya M. Turner C. Waldvogel H. J. Faull R. L. (2018). GABAA receptor subunit expression changes in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus.J. Neurochem.145374–392. 10.1111/jnc.14325
41
Lam P. Vinnakota C. Guzmán B. C.-F. Newland J. Peppercorn K. Tate W. P. et al (2022). Beta-amyloid (Aβ1-42) increases the expression of NKCC1 in the mouse hippocampus.Molecules27:2440. 10.3390/molecules27082440
42
Lauterborn J. C. Scaduto P. Cox C. D. Schulmann A. Lynch G. Gall C. M. et al (2021). Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer’s disease.Nat. Commun.12:2603. 10.1038/s41467-021-22742-8
43
Li S. Selkoe D. J. (2020). A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain.J. Neurochem.154583–597. 10.1111/jnc.15007
44
Li X. Long J. He T. Belshaw R. Scott J. (2015). Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer’s disease.Sci. Rep.5:12393. 10.1038/srep12393
45
Liang Y. Zhou Z. Wang H. Cheng X. Zhong S. Zhao C. (2019). Association of apolipoprotein E genotypes with epilepsy risk: A systematic review and meta-analysis.Epilepsy Behav.98(Pt A), 27–35. 10.1016/j.yebeh.2019.06.015
46
Limon A. Reyes-Ruiz J. M. Miledi R. (2012). Loss of functional GABA(A) receptors in the Alzheimer diseased brain.Proc. Natl. Acad. Sci. U. S. A.10910071–10076. 10.1073/pnas.1204606109
47
Lin Y.-M. Chu P.-H. Li Y.-Z. Ouyang P. (2017). Ribosomal protein pNO40 mediates nucleolar sequestration of SR family splicing factors and its overexpression impairs mRNA metabolism.Cell. Signal.3212–23. 10.1016/j.cellsig.2017.01.010
48
Lin Y.-M. Chu P.-H. Ouyang P. (2019). Ectopically expressed pNO40 suppresses ribosomal RNA synthesis by inhibiting UBF-dependent transcription activation.Biochem. Biophys. Res. Commun.516381–387. 10.1016/j.bbrc.2019.06.057
49
Lott I. T. Doran E. Nguyen V. Q. Tournay A. Movsesyan N. Gillen D. L. (2012). Down syndrome and dementia: Seizures and cognitive decline.J. Alzheimers Dis.29177–185. 10.3233/JAD-2012-111613
50
Maier F. C. Wehrl H. F. Schmid A. M. Mannheim J. G. Wiehr S. Lerdkrai C. et al (2014). Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion.Nat. Med.201485–1492. 10.1038/nm.3734
51
Mathern G. W. Pretorius J. K. Kornblum H. I. Mendoza D. Lozada A. Leite J. P. et al (1997). Human hippocampal AMPA and NMDA mRNA levels in temporal lobe epilepsy patients.Brain120(Pt 11), 1937–1959. 10.1093/brain/120.11.1937
52
Mathern G. W. Pretorius J. K. Leite J. P. Kornblum H. I. Mendoza D. Lozada A. et al (1998). Hippocampal AMPA and NMDA mRNA levels and subunit immunoreactivity in human temporal lobe epilepsy patients and a rodent model of chronic mesial limbic epilepsy.Epilepsy Res.32154–171. 10.1016/s0920-1211(98)00048-5
53
Minkeviciene R. Rheims S. Dobszay M. B. Zilberter M. Hartikainen J. Fülöp L. et al (2009). Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy.J. Neurosci.293453–3462. 10.1523/JNEUROSCI.5215-08.2009
54
Ning L. Shen R. Xie B. Jiang Y. Geng X. Dong W. (2024). AMPA receptors in Alzheimer disease: Pathological changes and potential therapeutic targets.J. Neuropathol. Exp. Neurol.83895–906. 10.1093/jnen/nlae093
55
Nygaard H. B. Kaufman A. C. Sekine-Konno T. Huh L. L. Going H. Feldman S. J. et al (2015). Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model.Alzheimers Res. Ther.7:25. 10.1186/s13195-015-0110-9
56
Osse A. M. L. Pandey R. S. Wirt R. A. Ortiz A. A. Salazar A. Kimmich M. et al (2023). Reduction in GABAB on glia induce Alzheimer’s disease related changes.Brain Behav. Immun.110260–275. 10.1016/j.bbi.2023.03.002
57
Palop J. J. Chin J. Roberson E. D. Wang J. Thwin M. T. Bien-Ly N. et al (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease.Neuron55697–711. 10.1016/j.neuron.2007.07.025
58
Palop J. J. Mucke L. (2009). Epilepsy and cognitive impairments in Alzheimer disease.Arch. Neurol.66435–440. 10.1001/archneurol.2009.15
59
Palop J. J. Mucke L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: From synapses toward neural networks.Nat. Neurosci.13812–818. 10.1038/nn.2583
60
Quiroz Y. T. Budson A. E. Celone K. Ruiz A. Newmark R. Castrillón G. et al (2010). Hippocampal hyperactivation in presymptomatic familial Alzheimer’s disease.Ann. Neurol.68865–875. 10.1002/ana.22105
61
Rahman M. M. Fatema K. (2019). Seizures in down syndrome: An update.Mymensingh Med. J.28712–715.
62
Ranasinghe K. G. Kudo K. Hinkley L. Beagle A. Lerner H. Mizuiri D. et al (2022). Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer’s disease.Brain145744–753. 10.1093/brain/awab442
63
Robinson J. L. Molina-Porcel L. Corrada M. M. Raible K. Lee E. B. Lee V. M.-Y. et al (2014). Perforant path synaptic loss correlates with cognitive impairment and Alzheimer’s disease in the oldest-old.Brain137(Pt 9), 2578–2587. 10.1093/brain/awu190
64
Romoli M. Sen A. Parnetti L. Calabresi P. Costa C. (2021). Amyloid-β: A potential link between epilepsy and cognitive decline.Nat. Rev. Neurol.17469–485. 10.1038/s41582-021-00505-9
65
Sanchez P. E. Zhu L. Verret L. Vossel K. A. Orr A. G. Cirrito J. R. et al (2012). Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model.Proc. Natl. Acad. Sci. U. S. A.109E2895–E2903. 10.1073/pnas.1121081109
66
Sarkis R. A. Dickerson B. C. Cole A. J. Chemali Z. N. (2016). Clinical and neurophysiologic characteristics of unprovoked seizures in patients diagnosed with dementia.J. Neuropsychiatry Clin. Neurosci.2856–61. 10.1176/appi.neuropsych.15060143
67
Selkoe D. J. (2002). Alzheimer’s disease is a synaptic failure.Science298789–791. 10.1126/science.1074069
68
Sepulveda-Falla D. Glatzel M. Lopera F. (2012). Phenotypic profile of early-onset familial Alzheimer’s disease caused by presenilin-1 E280A mutation.J. Alzheimers Dis.321–12. 10.3233/JAD-2012-120907
69
Shea Y.-F. Chu L.-W. Chan A. O.-K. Ha J. Li Y. Song Y.-Q. (2016). A systematic review of familial Alzheimer’s disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences.J. Formos. Med. Assoc.11567–75. 10.1016/j.jfma.2015.08.004
70
Sherzai D. Losey T. Vega S. Sherzai A. (2014). Seizures and dementia in the elderly: Nationwide inpatient sample 1999-2008.Epilepsy Behav.3653–56. 10.1016/j.yebeh.2014.04.015
71
Spires-Jones T. L. Hyman B. T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer’s disease.Neuron82756–771. 10.1016/j.neuron.2014.05.004
72
Sze C. I. Troncoso J. C. Kawas C. Mouton P. Price D. L. Martin L. J. (1997). Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease.J. Neuropathol. Exp. Neurol.56933–944. 10.1097/00005072-199708000-00011
73
Terry R. D. Masliah E. Salmon D. P. Butters N. DeTeresa R. Hill R. et al (1991). Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment.Ann. Neurol.30572–580. 10.1002/ana.410300410
74
Thom M. Liu J. Y. W. Thompson P. Phadke R. Narkiewicz M. Martinian L. et al (2011). Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: A post-mortem study.Brain134(Pt 10), 2969–2981. 10.1093/brain/awr209
75
Tomljanovic Z. Patel M. Shin W. Califano A. Teich A. F. (2018). ZCCHC17 is a master regulator of synaptic gene expression in Alzheimer’s disease.Bioinformatics34367–371. 10.1093/bioinformatics/btx608
76
Tönnies E. Trushina E. (2017). Oxidative stress, synaptic dysfunction, and Alzheimer’s disease.J. Alzheimers Dis.571105–1121. 10.3233/JAD-161088
77
Vicente M. Addo-Osafo K. Vossel K. (2024). Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with lewy bodies.Front. Neurol.15:1277613. 10.3389/fneur.2024.1277613
78
Volicer L. Smith S. Volicer B. J. (1995). Effect of seizures on progression of dementia of the Alzheimer type.Dementia6258–263. 10.1159/000106956
79
Vossel K. A. Beagle A. J. Rabinovici G. D. Shu H. Lee S. E. Naasan G. et al (2013). Seizures and epileptiform activity in the early stages of Alzheimer disease.JAMA Neurol.701158–1166. 10.1001/jamaneurol.2013.136
80
Vossel K. A. Ranasinghe K. G. Beagle A. J. Mizuiri D. Honma S. M. Dowling A. F. et al (2016). Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease.Ann. Neurol.80858–870. 10.1002/ana.24794
81
Vossel K. A. Tartaglia M. C. Nygaard H. B. Zeman A. Z. Miller B. L. (2017). Epileptic activity in Alzheimer’s disease: Causes and clinical relevance.Lancet Neurol.16311–322. 10.1016/S1474-4422(17)30044-3
82
Wakabayashi K. Narisawa-Saito M. Iwakura Y. Arai T. Ikeda K. Takahashi H. et al (1999). Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer’s disease.Neurobiol. Aging20287–295. 10.1016/s0197-4580(99)00035-4
83
Yang F. Chen L. Yu Y. Xu T. Chen L. Yang W. et al (2022). Alzheimer’s disease and epilepsy: An increasingly recognized comorbidity.Front. Aging Neurosci.14:940515. 10.3389/fnagi.2022.940515
84
Yu S. P. Choi E. Jiang M. Q. Wei L. (2025). Acute and chronic excitotoxicity in ischemic stroke and late-onset Alzheimer’s disease.Neural Regen. Res.201981–1988. 10.4103/NRR.NRR-D-24-00398
85
Zhou S. Yu Y. (2018). Synaptic E-I balance underlies efficient neural coding.Front. Neurosci.12:46. 10.3389/fnins.2018.00046
86
Zou Y. Wang C. Li H. Zhong M. Lin J. Hu Y. et al (2024). Epileptic seizures induced by pentylenetetrazole kindling accelerate Alzheimer-like neuropathology in 5×FAD mice.Front. Pharmacol.15:1500105. 10.3389/fphar.2024.1500105
Summary
Keywords
Alzheimer’s disease (AD), neuronal excitability, neuronal hyperexcitability, synaptic dysfunction, synaptic gene expression, ZCCHC17
Citation
Klub BA, Teich AF and Cortese GP (2026) ZCCHC17: a target for synaptic dysfunction and neuronal excitability in Alzheimer’s disease. Front. Aging Neurosci. 18:1737060. doi: 10.3389/fnagi.2026.1737060
Received
31 October 2025
Revised
26 January 2026
Accepted
28 January 2026
Published
10 February 2026
Volume
18 - 2026
Edited by
Keith Vossel, University of California, Los Angeles, United States
Reviewed by
Agenor Limon, University of Texas Medical Branch at Galveston, United States
Updates
Copyright
© 2026 Klub, Teich and Cortese.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giuseppe P. Cortese, giuseppe.cortese@mclaughlinresearch.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.